PROTEASE INHIBITOR SPONSORS KEEPING TIGHT CONTROL OVER NEW AGENTS; NIH HAS ASKED TO MOVE COMPOUNDS INTO GOVERNMENT TRIALS; ACCELERATED APPROVAL ISSUES RAISED
Manufacturers of protease inhibitors are maintaining strict control over new product development despite continuing overtures from the federal government to move the compounds into NIH clinical trials. Companies have opted to concentrate on individual pivotal trials rather than become involved in government trials aimed at a broader array of ancillary questions.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth